Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Cardio Diagnostics (NASDAQ:CDIO)

Cardio Diagnostics (NASDAQ:CDIO) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Volatility & Risk

Cardio Diagnostics has a beta of 2.94, suggesting that its stock price is 194% more volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

Insider and Institutional Ownership

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 13.3% of Cardio Diagnostics shares are held by insiders. Comparatively, 0.0% of Allarity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Cardio Diagnostics and Allarity Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$40,000.00	88.76	-$8.38 million	($3.74)	-0.52
Allarity Therapeutics	N/A	N/A	-$24.51 million	($0.59)	-1.93

Cardio Diagnostics has higher revenue and earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cardio Diagnostics and Allarity Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1	0	0	0	1.00
Allarity Therapeutics	1	0	1	0	2.00

Allarity Therapeutics has a consensus target price of $9.50, suggesting a potential upside of 733.33%. Given Allarity Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Cardio Diagnostics.

Profitability

This table compares Cardio Diagnostics and Allarity Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-39,674.18%	-67.51%	-62.27%
Allarity Therapeutics	N/A	-112.05%	-64.89%

Summary

Cardio Diagnostics beats Allarity Therapeutics on 7 of the 13 factors compared between the two stocks.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

About Allarity Therapeutics

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.